71 Investor presentation Full year 2023 Phase 3 trial programme for oral overweight or obesity, OASIS Oral semaglutide characteristics Oral semaglutide 50mg: • Semaglutide tablets in overweight or obesity • Once daily tablet Phase 3a programme with oral semaglutide 50 mg • Aims to confirm efficacy and safety • Submitted in EU in 2023, submission in US expected during 2024 • The global launch of oral semaglutide 50 mg is contingent on portfolio prioritisations and manufacturing capacity OASIS 1 50 mg dose OASIS 2 EAST ASIA OASIS 3 China OASIS 4 25 mg dose • 667 pati • 68 week • Primary • 198 pati • 68 week • Primary 2022 BW: Body weight; T2D: Type 2 diabetes
Download PDF file